Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.
J Thorac Oncol
; 18(9): 1209-1221, 2023 09.
Article
en En
| MEDLINE
| ID: mdl-37236398
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Neoplasias Pulmonares
Tipo de estudio:
Clinical_trials
/
Guideline
/
Qualitative_research
Límite:
Humans
Idioma:
En
Revista:
J Thorac Oncol
Año:
2023
Tipo del documento:
Article